It’s 2028. One of the world’s leading genome-editing companies is crowing about receiving regulatory approval for a lifesaving therapy for Duchenne muscular dystrophy, based on the genome-editing technology CRISPR-Cas9. But its celebration is cut short: A rival files a lawsuit arguing that the therapy infringes on a CRISPR patent that the rival has exclusive rights to. The next day, a judge issues an injunction ordering the company to stop selling the $1 million therapy. As the weeks pass, headlines around the world show crippled boys, who had been scheduled to receive the genetic cure, crying tears of despair. Patient groups launch a website showing how many children have died since the injunction and picket the headquarters of the litigious company, carrying mock tombstones with the names of the dead boys.

It’s 2028. One of the world’s leading genome-editing companies is crowing about receiving regulatory approval for a lifesaving therapy for Duchenne muscular dystrophy. But its rivals are also celebrating. Under the terms of an agreement reached in 2018, companies, universities, and other institutions that made overlapping genome-editing discoveries will share in the revenues from therapies each of the others developed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy